Informational Only · Not Legal Advice · No Attorney-Client Relationship · Editorial Policy

A Medical Stapler Misfiring During Surgery: What Could Make a Settlement Offer Fair—or Dangerously Low?

A settlement offer for a surgical stapler injury is fair only when it reflects three things: the full medical and life-care cost of the failure, the strength of the proof that the device itself malfunctioned, and the liens that will be taken out of the money before you see it. An offer is dangerously low when it is priced as a surgical complication — an accepted risk of the operation — rather than as a product failure, because that framing quietly erases the manufacturer's share of the loss.

Surgical staplers close tissue with rows of metal staples instead of sutures, and they are used in bowel, lung, bariatric, and gynecologic operations where a leak is catastrophic. When one misfires, the injury is rarely the staple line alone: it is sepsis, emergency reoperation, a colostomy, months of recovery, and sometimes death. The number attached to that has to be built from the damages, not from what an adjuster calls a reasonable complication payout.

Table of Contents

What "misfiring" actually means, and why it points at the device

The FDA has catalogued the specific ways these devices fail. In its March 2019 announcement, the FDA described the failure modes as staple-line openings, malformed staples, misfiring, difficulty firing, failure to fire, and misapplied staples — and said proper staple formation depends largely on the stapler working correctly. That last point is the one that matters to a settlement.

Defense arguments in these cases usually start and end with surgical technique: the surgeon placed it wrong, fired through tissue that was too thick, stapled a compromised bowel. The FDA's own framing establishes that many of these events belong to the device, not the operator. The agency's volume numbers show this is not a rare event class. Between January 1, 2011 and March 31, 2018, the FDA received roughly 41,000 medical device reports for surgical staplers and implantable staples, including 366 deaths, more than 9,000 serious injuries, and over 32,000 malfunctions.

Why these claims survive preemption — and what that is worth

Preemption is the rule that federal device approval can block state-law injury claims. It is the single biggest reason some medical device cases are worth very little and others are worth a great deal, and most injured people have never heard of it. The distinction turns on how the device reached the market. In Riegel v. Medtronic, decided 8-1 in 2008, the Supreme Court held that devices cleared through the rigorous premarket approval process are shielded from state design-defect and failure-to-warn claims.

Devices cleared through the lighter 510(k) pathway are not, under Medtronic v. Lohr. Surgical staplers went through 510(k). That means design-defect and failure-to-warn theories remain live, in addition to manufacturing-defect claims. An offer that treats your case as a weak, preemption-constrained device claim is mispriced. The regulatory picture also tightened: the FDA's final order effective October 8, 2021 reclassified internal surgical staplers from Class I to Class II with special controls, and the Federal Register notice required manufacturers of already-marketed staplers to obtain 510(k) clearance within 180 days.

The defendant's "clean record" may not be clean

A standard move in negotiation is to point at the public complaint history and argue the device has no meaningful track record of failure. That argument rests on the FDA's MAUDE database, which is the public adverse-event record — and for staplers, MAUDE was missing most of the story. A 2019 Kaiser Health News investigation found that more than 56,000 stapler malfunction reports from 2011 through 2018 went into the FDA's non-public Alternative Summary Reporting program instead of MAUDE. In 2016 alone, only 84 stapler injury and malfunction reports were publicly visible while nearly 10,000 were filed into the hidden database.

Recall history is the other record to check, and it is public. The FDA classified an Ethicon recall of about 92,496 curved intraluminal staplers, made March 2018 through March 2019, as Class I after uncut washers and malformed staples were found — an uncut washer indicating a complete 360-degree staple line failure. A second Ethicon recall, of Echelon Flex Endopath staplers with an out-of-specification jaw component, was classified Class I on October 30, 2019, with seven serious injuries and one death reported as of October 3, 2019. If your surgery date and device lot fall inside a recall window, that is leverage an early offer almost certainly does not reflect.

Measuring an offer against what these cases have actually produced

Verdicts are the ceiling that gives a settlement number its context. A California federal jury awarded about $79.8 million against Ethicon in 2015 on manufacturing-defect and design findings, as HarrisMartin reported from the trial. A Florida jury awarded Paul McGowan $9.3 million over an Ethicon Endo-Surgery stapler. But severity alone does not deliver those numbers.

A 2017 Illinois wrongful-death stapler case settled for $5.5 million in total, and the device maker, Covidien, paid only $250,000 of it — because it disputed that any defect caused the death. The rest came from other defendants. That case is the clearest warning available: causation proof against the manufacturer, not how badly the patient was hurt, drove the manufacturer's share. So the honest test of an offer is not "is this a lot of money." It is whether the offer matches the strength of the causation evidence in your specific file:.

  • Was the device retained and preserved after the operation, or discarded? A retained stapler that can be examined is the difference between a defect theory and a hypothesis.
  • Does the operative report describe a staple line failure, malformed staples, or a misfire, in those terms?
  • Does the device's lot number fall within a Class I recall?
  • Is there a treating surgeon willing to say the device malfunctioned, as opposed to declining to comment on the device at all?
  • Did the hospital file an adverse-event report, and can it be obtained?

The lien that makes a fair-looking offer too low

The number you are offered is not the number you keep. The Medicare Secondary Payer statute, 42 U.S.C. § 1395y(b), gives Medicare a right to recover from settlement proceeds the conditional payments it made for treatment related to your injury. A sepsis admission, a reoperation, and a long ICU stay can generate a very large conditional-payment total.

The practical danger is timing. Early conditional-payment letters are interim figures, and the final demand can come in higher — a point borne out in Medicare appeals decisions published by HHS. An offer evaluated gross of the lien can look adequate and leave almost nothing after reimbursement, attorney fees, and case costs. Before accepting anything, ask for the settlement calculated net: offer, minus the current conditional-payment figure, minus fees and costs, with an explicit note about which charges are being disputed as unrelated to the injury. Medicare's demand is negotiable on relatedness, and that negotiation should happen before you sign, not after.

What to do in the first weeks

The window for preserving the evidence that sets your case's value closes fast, and most of it closes inside the hospital. If the device itself was discarded, the case is not over, but its shape changes: the claim then leans on the operative findings, the recall record, and the manufacturer's reporting history rather than on physical inspection — and an offer should be read against that reality, not against the $79.8 million verdict headline.

  • Send a written preservation request to the hospital for the device, its packaging, the lot number, and the sterile-processing records before anything is discarded.
  • Request the complete operative report, the pathology report, and any adverse-event report filed with the manufacturer or the FDA.
  • Write down the manufacturer and model name while it is still recoverable from the chart; "a stapler" is not a defendant.
  • Check the date of your surgery against the Ethicon recall windows above, and keep the lot number with the file.
  • Ask any lawyer evaluating an offer to show you the net figure after the Medicare conditional-payment demand, not the gross.

Frequently Asked Questions

Does it matter that my surgeon, not the manufacturer, was holding the device?

Not necessarily. The FDA has stated that proper staple formation depends largely on the stapler functioning correctly, which supports a device claim even where the surgeon performed the operation normally. Cases often proceed against both the hospital or surgeon and the manufacturer, and as the Illinois case shows, the split between them can be very uneven.

Why does the 510(k) pathway help my case?

Because preemption only blocks state design-defect and failure-to-warn claims for devices that went through full premarket approval. Staplers were cleared through 510(k), so those theories remain available — which generally raises what a case is worth compared with a device shielded under Riegel.

The manufacturer says there were almost no complaints about this device. Is that reliable?

Treat it as incomplete. Tens of thousands of stapler malfunction reports from 2011 to 2018 were routed into a non-public FDA reporting program rather than the public MAUDE database, so a thin public record does not establish a thin actual record.

Should I accept an offer before the Medicare conditional-payment amount is final?

Only with the risk priced in. Interim conditional-payment letters can be lower than the final demand, so an offer that looks reasonable gross can net far less. Resolve or at least bracket the relatedness dispute before signing.


You Might Also Like

We use essential cookies to make this site work and remember your preferences. We do not use advertising or analytics cookies. Privacy Policy.